Abstract
Lisuride is a soluble ergolene derivative with endocrine effects similar to but more potent than those of bromocriptine. In nine subjects with idiopathic, postencephalitic, or drug-induced parkinsonism, lisuride at a dosage of 0.05 to 0.15 mg intravenously caused an immediate improvement in tremor, rigidity, akinesia, and postural deformity, but also caused chorea and orofacial dyskinesia. Improvement lasted 2 to 3 hours. Lisuride had little or no effect in a single patient with progressively supranuclear palsy. Oral lisuride therapy, 0.8 to 4.8 mg daily, had similar effects but occasionally caused reduced awareness and hallucinations.
MeSH terms
-
Administration, Oral
-
Aged
-
Benzimidazoles / administration & dosage
-
Chorea / chemically induced
-
Domperidone
-
Dose-Response Relationship, Drug
-
Drug Therapy, Combination
-
Dyskinesia, Drug-Induced / etiology
-
Ergolines / therapeutic use*
-
Female
-
Growth Hormone / blood
-
Humans
-
Injections, Intravenous
-
Lisuride / administration & dosage
-
Lisuride / therapeutic use*
-
Male
-
Middle Aged
-
Paralysis / drug therapy
-
Parkinson Disease / drug therapy*
-
Parkinson Disease, Postencephalitic / drug therapy
-
Parkinson Disease, Secondary / chemically induced
-
Piperidines / administration & dosage
-
Prolactin / blood
Substances
-
Benzimidazoles
-
Ergolines
-
Piperidines
-
Domperidone
-
Prolactin
-
Growth Hormone
-
Lisuride